Morgan Stanley’s Genprex GNPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Hold
0
8206
2025
Q4
Sell
-1
Closed -$141 8128
2025
Q3
$162 Hold
1
﹤0.01% 7621
2025
Q2
$218 Hold
1
﹤0.01% 7560
2025
Q1
$235 Sell
1
-8
-89% -$4.44K ﹤0.01% 7458
2024
Q4
$7.98K Buy
9
+8
+800% +$10.5K ﹤0.01% 6878
2024
Q3
$569 Hold
1
﹤0.01% 7288
2024
Q2
$2.8K Hold
1
﹤0.01% 6998
2024
Q1
$4.46K Sell
1
-2
-67% -$13.2K ﹤0.01% 6921
2023
Q4
$27.4K Buy
3
+2
+200% +$23.1K ﹤0.01% 6550
2023
Q3
$17.7K Hold
1
﹤0.01% 6524
2023
Q2
$23.5K Buy
+1
New +$37.2K ﹤0.01% 6514
2023
Q1
Hold
0
6808
2022
Q4
Hold
0
6719
2022
Q3
Hold
0
6886
2022
Q2
Sell
-1
Closed -$70.4K 6899
2022
Q1
$76K Sell
1
-19
-95% -$1.85M ﹤0.01% 6481
2021
Q4
$1.13M Buy
20
+18
+900% +$1.5M ﹤0.01% 4988
2021
Q3
$257K Sell
2
-2
-50% -$259K ﹤0.01% 5866
2021
Q2
$661K Buy
+4
New +$656K ﹤0.01% 5342
2021
Q1
Sell
-1
Closed -$220K 6080
2020
Q4
$129K Buy
+1
New +$155K ﹤0.01% 5802
2020
Q3
Hold
0
5644
2020
Q2
Hold
0
5639
2020
Q1
Hold
0
6106
2019
Q4
Hold
0
6687
2019
Q3
Hold
0
6675
2019
Q2
Hold
0
6680
2019
Q1
Hold
0
6628
2018
Q4
Hold
0
6638
2018
Q3
Hold
0
6742
2018
Q2
Hold
0
6588

Other funds holding GNPX

Morgan Stanley's GNPX Position: Q1 2026 in Review

Morgan Stanley held its Genprex (GNPX) position steady in Q1 2026 at 0 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #8206.

Morgan Stanley first reported a position in GNPX in Q4 2020 and has held it in 15 quarters since. The position peaked at $1.13M in Q4 2021. 15 funds tracked by Wall St. Rank hold GNPX as of Q1 2026.

  • Morgan Stanley held 0 shares of Genprex worth $11 as of Q1 2026.
  • Morgan Stanley left its Genprex share count unchanged in Q1 2026.
  • Genprex made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8206 holding.
  • Morgan Stanley first reported a position in Genprex in Q4 2020 and has held it in 15 quarters since.
  • Morgan Stanley's Genprex position peaked at $1.13M in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Genprex as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.